HeartBeam, Inc. Form 8-K Summary
Reporting date: February 18, 2022; filed February 22, 2022. The filing reports a material definitive agreement and an unregistered equity securities offering.
Business Context and Transaction
HeartBeam entered into a stock purchase agreement with OpenSky Opportunities Fund Ltd. for a private placement of 58,000 units at $6 per unit. Each unit comprised one share of common stock and one warrant to purchase one additional share of common stock.
- Gross offering amount: $348,000.
- Net proceeds: $348,000; the company reported no underwriting discounts or commissions.
- Warrants: Exercise price of $6.00 per share, exercisable immediately subject to a 180-day lock-up, and expiring five years from issuance.
- Use of proceeds: General working capital and other corporate purposes.
- Registration: Securities were not registered under the Securities Act and were issued under Section 4(a)(2) and Rule 506 of Regulation D to an accredited investor without general solicitation.
Financial Metrics and Liquidity
This 8-K does not provide revenue, profit, cash-flow, margin, debt, balance-sheet, or broader liquidity figures. The reported $348,000 of net proceeds is expected to provide additional working capital, but the filing does not quantify the company’s resulting cash balance or cash runway.
Material Changes and Investor Implications
- The transaction increases cash resources by $348,000 before considering subsequent activity.
- The issuance added 58,000 common shares and warrants exercisable for up to 58,000 additional shares, creating potential dilution to existing shareholders.
- The filing does not provide a prior comparable period or quantify the percentage dilution relative to shares outstanding.
Outlook, Risks, and Unusual Items
Management stated only that proceeds would be used for general working capital and corporate purposes. No formal guidance or operating outlook was provided.
- Future warrant exercises could result in additional common-stock dilution.
- The securities were issued in an unregistered private placement and may be subject to transfer restrictions.
- The filing does not describe specific contingencies, litigation, debt covenants, or other unusual items.
Key Facts to Verify
- Confirm the final number of common shares issued and the company’s post-transaction shares outstanding.
- Review the Stock Purchase Agreement and Form of Warrant filed as Exhibit 10.1 for lock-up, exercise, transfer, and other terms.
- Assess the company’s cash balance and liquidity after receipt of the proceeds.
- Evaluate potential dilution from both the issued shares and the warrants.
- Note that the filing’s text refers to an unregistered sale under Item 3.01, while the transaction description corresponds to the unregistered securities sale disclosure typically addressed under Item 3.02.